1
|
Gamsby JJ, Templeton EL, Bonvini LA, Wang W, Loros JJ, Dunlap JC, Green AI, Gulick D. The circadian Per1 and Per2 genes influence alcohol intake, reinforcement, and blood alcohol levels. Behav Brain Res 2013; 249:15-21. [PMID: 23608482 DOI: 10.1016/j.bbr.2013.04.016] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 04/09/2013] [Accepted: 04/13/2013] [Indexed: 11/26/2022]
Abstract
BACKGROUND Perturbations in the function of core circadian clock components such as the Period (Per) family of genes are associated with alcohol use disorder, and disruptions in circadian cycles may contribute to alcohol abuse and relapse. This study tested ethanol consumption, reinforcement, and metabolism in mice containing functional mutations in Per1 and/or Per2 genes on an ethanol-preferring background, C57BL/6J mice. METHODS Mice were tested in: (A) free-access intake with ascending concentrations of ethanol (2-16%, v/v), (B) conditioned place preference using ethanol (2g/kg for males; 2.5g/kg for females) vs. saline injections, (C) recovery of the righting reflex following a 4g/kg bolus of ethanol, and (D) blood ethanol levels 1h after a 2g/kg bolus of ethanol. RESULTS All Per mutant (mPer) mice showed increased ethanol intake and condition place preference compared to controls. There were also genotypic differences in blood ethanol concentration: in males, only mPer1 mice showed a significantly higher blood ethanol concentration than WT mice, but in females, all mPer mice showed higher blood ethanol levels than WT mice. CONCLUSIONS Mutation of either Per1 or Per2, as well as mutations of both genes, increases ethanol intake and reinforcement in an ethanol-preferring mouse model. In addition, this increase in ethanol seeking behavior seems to result both from a change in ethanol metabolism and a change in reward responding to ethanol, but not from any change in sensitivity to ethanol's sedating effects.
Collapse
Affiliation(s)
- J J Gamsby
- Department of Genetics, Geisel School of Medicine at Dartmouth, United States
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006; 86:234-43. [PMID: 16887334 DOI: 10.1016/j.schres.2006.06.021] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2005] [Revised: 06/08/2006] [Accepted: 06/14/2006] [Indexed: 11/30/2022]
Abstract
Few studies have assessed the comparative efficacy and safety of atypical and typical antipsychotic medications in patients within their first episode of psychosis. This study examined the effectiveness of the atypical antipsychotic olanzapine and the typical antipsychotic haloperidol in patients experiencing their first episode of a schizophrenia-related psychotic disorder over a 2-year treatment period. Two hundred and sixty-three patients were randomized to olanzapine or haloperidol in a doubleblind, multisite, international 2-year study. Clinical symptoms and side effects were assessed at baseline and longitudinally following randomization for the duration of the study. Olanzapine and haloperidol treatment were both associated with substantial and comparable reductions in symptom severity (the primary outcome measure) over the course of the study. However, the treatment groups differed on two secondary efficacy measures. Patients were less likely to discontinue treatment with olanzapine than with haloperidol: mean time (in days) in the study was significantly greater for those treated with olanzapine compared to haloperidol (322.09 vs. 230.38, p<0.0085). Moreover, remission rates were greater in patients treated with olanzapine as compared to those treated with haloperidol (57.25% vs. 43.94%, p<0.036). While extrapyramidal side effects were greater in those treated with haloperidol, weight gain, cholesterol level and liver function values were greater in patients treated with olanzapine. The data from this study suggest some clinical benefits for olanzapine as compared to haloperidol in first episode patients, which must be weighed against those adverse effects that are more likely with olanzapine.
Collapse
Affiliation(s)
- A I Green
- Department of Psychiatry, Dartmouth Medical School, DHMC, Lebanon, NH 03756, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
BACKGROUND Many first-degree relatives of patients with schizophrenia show deficits in clinical, neuropsychological, neurobiological and social domains, in the absence of psychosis. We recently reformulated Meehl's concept of schizotaxia to conceptualize the liability to schizophrenia, and we proposed preliminary criteria based on the presence of negative symptoms and neuropsychological deficits. Here we investigate the concurrent validity of schizotaxia by comparing a group of subjects who met criteria for schizotaxia with a group who did not on independent measures of clinical function, and on lifetime rates of selected comorbid psychiatric disorders. METHODS Twenty-seven adults who were first-degree, biological relatives of patients with schizophrenia were evaluated for schizotaxia based on our predetermined criteria involving negative symptoms and neuropsychological deficits. Subjects also received portions of the Diagnostic Interview for Genetic Studies, the Structured Interview for Schizotypy, the Family Interview for Genetic Studies, the DSM-IV Global Assessment of Functioning, the Physical Anhedonia Scale, the Social Adjustment Scale and the Symptom Checklist-90-Revised. Subjects who met criteria for schizotaxia were compared with those who did not on each of the clinical measures, and on their rates of comorbid DSM-IV psychiatric diagnoses. RESULTS Eight subjects met criteria for schizotaxia, and 19 did not. Subjects with schizotaxia showed significantly lower levels of function on each of the clinical scales. Differences in comorbid psychiatric diagnoses were not significant, although the rate of lifetime substance abuse diagnoses in the schizotaxic group (50%) approached levels that are often seen in schizophrenia. CONCLUSIONS These findings provide the first evidence of concurrent validation for a proposed syndrome of schizotaxia. They are also consistent with the view that the vulnerability to schizophrenia may be defined, at least partially, although larger studies to assess both the concurrent and predictive validity of schizotaxia will be required to confirm these results.
Collapse
Affiliation(s)
- W S Stone
- Department of Psychiatry at Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
| | | | | | | | | | | |
Collapse
|
4
|
Abstract
We sought to show that (1) schizotaxia (Meehl's term for the predisposition to schizophrenia) is a clinically consequential condition, and (2) distinguishing it from schizotypal personality disorder may be useful from both clinical and scientific perspectives. We review the features of schizotaxia that may be relevant in clinical settings and discuss their implications for the diagnosis, psychosocial functioning, family intervention and treatment of people in schizophrenia families. Our review indicates that prior work finds some of the nonpsychotic and nonschizotypal relatives of schizophrenia patients to have a psychiatric syndrome characterized by negative symptoms, neuropsychological impairment, and psychosocial dysfunction. Following Meehl, we call this constellation of clinical and neurobiological features schizotaxia. The studies we review suggest it may be worthwhile to consider schizotaxia as a separate diagnostic class. Doing so would alert clinicians to a neurobehavioral syndrome not adequately covered by current diagnostic criteria and would motivate researchers to develop diagnostic and therapeutic approaches aimed at helping schizotaxic individuals and, perhaps, preventing the onset of schizophrenia.
Collapse
|
5
|
Abstract
Several case studies indicate that clozapine use is associated with reductions in the use of nicotine, alcohol, or illicit drugs. Although not designed to assess clozapine, this study explored a posteriori the effects of clozapine on alcohol and drug use disorders among schizophrenia patients. Among 151 patients with schizophrenia or schizoaffective disorder and co-occurring substance use disorder who were studied in a dual-disorder treatment program, 36 received clozapine during the study for standard clinical indications. All participants were assessed prospectively at baseline and every 6 months over 3 years for psychiatric symptoms and substance use. Alcohol-abusing patients taking clozapine experienced significant reductions in severity of alcohol abuse and days of alcohol use while on clozapine. For example, they averaged 54.1 drinking days during 6-month intervals while off clozapine and 12.5 drinking days while on clozapine. They also improved more than patients who did not receive clozapine. At the end of the study, 79.0 percent of the patients on clozapine were in remission from alcohol use disorder for 6 months or longer, while only 33.7 percent of those not taking clozapine were remitted. Findings related to other drugs in relation to clozapine were also positive but less clear because of the small number of patients with drug use disorders. This study was limited by the naturalistic design and the lack of prospective, standardized measures of clozapine use. The use of clozapine by patients with co-occurring substance disorders deserves further study in randomized clinical trials.
Collapse
Affiliation(s)
- R E Drake
- New Hampshire-Dartmouth Psychiatric Research Center, Dartmouth Medical School, Lebanon, NH, USA.
| | | | | | | |
Collapse
|
6
|
Green AI. What is the relationship between schizophrenia and substance abuse? Harv Ment Health Lett 2000; 17:8. [PMID: 11015759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/15/2023]
|
7
|
Abstract
Obesity is common in schizophrenia, and people with schizophrenia appear to be at increased risk for certain obesity-related conditions, such as type 2 diabetes and cardiovascular disease. Antipsychotic drugs, used chronically to control symptoms of schizophrenia, are associated with often-substantial weight gain, a side effect that is a special concern with the latest generation of highly effective "novel" agents. That the most effective (e.g., novel) antipsychotic medications lead to substantial weight gain presents the field with a critical public health problem. Although preliminary data have been reported regarding the beneficial use of behavior therapy programs for short-term weight control in patients with schizophrenia, the available data are quite limited, and there are no data regarding the long-term beneficial effects of these programs in this population. The obesity field recently has developed programs emphasizing "lifestyle changes" (e.g., diet, exercise, and problem-solving skills) to successfully manage weight in patients without schizophrenia. Such programs can be adapted for patients with schizophrenia through the use of highly structured and operationalized modules emphasizing medication compliance, social skills development, and participation in outpatient programs. Moreover, these programs can potentially be combined with the use of adjunctive pharmacotherapy to maximize and maintain weight loss. The field must solve the paradox that some of our most effective medications for schizophrenia produce substantial weight gain and its associated troubling health risks.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Harvard Medical School Department of Psychiatry, Boston, Massachusetts 02115, USA
| | | | | | | | | |
Collapse
|
8
|
Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000; 157:982-6. [PMID: 10831480 DOI: 10.1176/appi.ajp.157.6.982] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The efficacy of clozapine was examined in a group of patients with treatment-refractory bipolar disorder, manic type with psychotic features. METHOD Twenty-two subjects with treatment-refractory bipolar disorder with active manic and psychotic symptoms participated in a 12-week open-label trial of clozapine. After a 2-10-day drug washout period, patients began treatment with clozapine at 25 mg/day; the dose was increased 25 mg/day (as tolerated) to a maximum level of 550 mg/day. Patients were evaluated longitudinally over the course of the study with the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale, and the Clinical Global Impressions (CGI) scale. RESULTS Fourteen of the 22 subjects in the study continued taking clozapine for at least 10 of the 12 weeks. Among the entire group, mean improvements of 56. 7%, 56.6%, and 39.1% were seen on the BPRS, Young Mania Rating Scale, and CGI, respectively. Seventeen of the 22 subjects (77.3%) experienced at least a 20% improvement in scores on all three scales. CONCLUSIONS The findings from this open-label study, which are consistent with previous retrospective studies, case reports, and one other open-label prospective study, suggest that clozapine is an effective agent for patients with treatment-refractory psychotic mania.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000; 20:94-8. [PMID: 10653215 DOI: 10.1097/00004714-200002000-00016] [Citation(s) in RCA: 110] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Substance use disorders, particularly those involving alcohol, marijuana, and cocaine, are highly prevalent among patients with schizophrenia and contribute markedly to its overall morbidity. Unfortunately, standard (typical) antipsychotic medications do not seem to reduce substance use in patients with schizophrenia and may even increase it. Recently, however, a few anecdotal case reports and two previous small "N" surveys have found that clozapine, an atypical antipsychotic medication, seems to decrease substance use in patients treated with this drug for their psychoses. The authors report data from a retrospective survey of substance use in 58 patients treated with clozapine who had a history of comorbid schizophrenia (or schizoaffective disorder) and substance use disorder. Of these 58 patients, 43 were being treated with clozapine at the time of the survey; the remaining 15 patients had discontinued clozapine before the survey. The survey involved chart review and clinician interview to assess change in substance use and global clinical symptoms while receiving treatment with clozapine. More than 85% of the patients who were active substance users at the time of initiation of treatment with clozapine decreased their substance use over the course of clozapine administration. For patients who continued treatment with clozapine up to the present, the decrease in substance use was strongly correlated with a decrease in global clinical symptoms. Data from this retrospective survey further support the previous observations that clozapine reduces substance use among patients with schizophrenic disorders. Moreover, the data suggest the need for prospective controlled studies of the effects of clozapine on substance use in this population.
Collapse
Affiliation(s)
- S V Zimmet
- Commonwealth Research Center, Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | | |
Collapse
|
10
|
|
11
|
Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher JP, Green AI. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry 1999; 45:1412-8. [PMID: 10356622 DOI: 10.1016/s0006-3223(98)00364-3] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Substantial evidence now shows that the genetic vulnerability to schizophrenia can be manifested clinically in first-degree relatives of people with schizophrenia, even without the full manifestations of the disorder. One pattern of problems observed involves the combination of negative symptoms and neuropsychological deficits. We have investigated whether a low dose of a novel antipsychotic medication, risperidone, could attenuate these clinical problems in non-psychotic, first-degree relatives, and report here findings from our first 4 cases. METHODS Twelve adults who were first-degree relatives of patients with schizophrenia were evaluated for the presence of negative symptoms and neuropsychological deficits (in attention and working memory, long-term verbal memory and executive functions). Four subjects who met our predetermined criteria, and who did not demonstrate medical contraindications, were enrolled in a 6-week trial of risperidone. Clinical and medical measures were assessed before, during and after treatment. Doses of risperidone started at 0.25 mg and were increased to 1.0-2.0 mg/day. RESULTS These subjects showed substantial reductions in negative symptoms, and one subject showed modest reductions. All four subjects showed substantial improvements on some tests of attention and working memory. Side effects of risperidone were temporary and mainly mild. CONCLUSIONS These initial findings support two conclusions. First, clinical deficits in non-psychotic first-degree relatives of people with schizophrenia are identifiable, and to a significant extent, reversible. Second, risperidone may eventually serve as an effective treatment for people whose lives are impaired by similar or related problems.
Collapse
Affiliation(s)
- M T Tsuang
- Harvard Medical School, Department of Psychiatry, Massachusetts Mental Health Center (MMHC), Boston 02115, USA
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999; 6:287-96. [PMID: 10370435 DOI: 10.3109/10673229909017206] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Alcohol and other drugs of abuse are commonly used by persons with schizophrenia and contribute to the overall morbidity of the disorder. Standard, or typical, antipsychotic drugs do not limit such substance use and may even render it more likely. However, preliminary data from our group and others suggest that the atypical antipsychotic clozapine may decrease substance use in this population. While recognizing the likelihood that substance use decreases negative symptoms (as well as extrapyramidal symptoms) in persons with schizophrenia, we hypothesize that the biological basis of substance use relates to a "reward-deficiency syndrome" secondary to dysfunctional dopamine-mediated mesocorticolimbic neurons in these individuals. We further suggest that clozapine's beneficial effect in patients with comorbid schizophrenia and substance use disorders may relate to its presumed ability to ameliorate the deficits in both the mesocortical and mesolimbic dopaminergic neuronal projections through its various actions on dopaminergic, serotonergic, and particularly noradrenergic neurons.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Massachusetts Mental Health Center, Boston 02115, USA
| | | | | | | |
Collapse
|
13
|
Canuso CM, Goldstein JM, Green AI. The evaluation of women with schizophrenia. Psychopharmacol Bull 1998; 34:271-7. [PMID: 9803753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Schizophrenia affects approximately 1 percent of the population worldwide. Its manifestation and response to treatment are often different in women and men and sex hormones, such as estrogen, may help to explain some of these phenomenological and clinical differences. This article reviews important sex differences in symptom expression and treatment response of schizophrenia and focuses on gender-specific factors, such as motherhood, that require specific methods of assessment in women with the disorder. The evaluation of suicide risk, substance abuse, and medical comorbidity in women with schizophrenia is also addressed. Particular attention is paid to the evaluation needs of women receiving antipsychotics, some of which elevate serum prolactin levels.
Collapse
Affiliation(s)
- C M Canuso
- Commonwealth Research Center, Massachusetts Mental Health Center, Boston 02115, USA
| | | | | |
Collapse
|
14
|
|
15
|
Berman I, Merson A, Viegner B, Losonczy MF, Pappas D, Green AI. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. J Nerv Ment Dis 1998; 186:150-6. [PMID: 9521350 DOI: 10.1097/00005053-199803000-00003] [Citation(s) in RCA: 119] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Using neurocognitive testing, the present study assessed whether obsessions and compulsions could represent a distinct cluster of symptoms in schizophrenia. We formulated our hypothesis based on data from nonschizophrenic patients, expecting to find that schizophrenic patients with obsessive-compulsive (OC) symptoms would experience more difficulties in the same cognitive areas as nonschizophrenic patients with obsessive-compulsive disorder (OCD). Patients had separate psychiatric and cognitive evaluations. The OC and non-OC schizophrenic subjects did not differ significantly on the positive and negative symptom scores. However, compared with non-OC schizophrenic patients, those with OC symptoms performed worse on cognitive areas thought to be impaired (i.e., visual-spatial skills, delayed nonverbal memory, and cognitive shifting abilities). In addition, the severity of OC scores correlated with poor performance in these areas of cognition. Our results support our hypothesis, specifically that OC symptoms may constitute a distinct cluster separate from psychosis in schizophrenia and raise the possibility of a distinct subtype of schizophrenia. The theoretical and clinical implications of these findings are discussed.
Collapse
Affiliation(s)
- I Berman
- Taunton State Hospital, Harvard Medical School, Massachusetts 02780-0997, USA
| | | | | | | | | | | |
Collapse
|
16
|
Affiliation(s)
- J K Patel
- Commonwealth Research Center, Massachusetts Mental Health Center, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
17
|
Kando JC, Shepski JC, Satterlee W, Patel JK, Reams SG, Green AI. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 1997; 31:1325-34. [PMID: 9391688 DOI: 10.1177/106002809703101110] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of olanzapine as a treatment for schizophrenia and to determine the advantages and disadvantages of this atypical antipsychotic agent compared with currently marketed agents. DATA SOURCES A MEDLINE computer literature search was conducted to retrieve all English-language studies and review articles involving olanzapine published as of October 1, 1996. The manufacturer of the drug, Eli Lilly and Company, provided the clinical investigator's brochure and abstracts of unpublished Phase III clinical trials. STUDY SELECTION Animal studies evaluating the pharmacology of olanzapine were evaluated, as were all open-label and double-blind studies involving the evaluation of olanzapine for the treatment of patients with schizophrenia. DATA EXTRACTION All available clinical studies were reviewed and the interpretation of data for each study was influenced by the size of the study sample, the nature of the inclusion and exclusion criteria, and the data analysis techniques used. DATA SYNTHESIS Olanzapine is a thienobenzodiazepine analog with an in vitro receptor affinity profile similar to that of clozapine. Olanzapine exhibits linear kinetics over the dosage range studied and is extensively metabolized in humans. Clinical evaluations to date have shown olanzapine to be at least as efficacious as typical antipsychotic agents in the treatment of the acute phase of schizophrenia. The drug was well tolerated, with significantly fewer extrapyramidal adverse effects than haloperidol. Current data suggest that olanzapine may be more effective than haloperidol for the treatment of negative symptoms; moreover, preliminary data suggest that fewer relapses occur over the course of treatment in patients treated with olanzapine compared with those taking haloperidol. CONCLUSIONS The exact place of olanzapine in the therapy of psychotic patients remains unclear, as more data are needed to evaluate the long-term efficacy of this agent, its impact on negative symptoms, and its potential use in patients resistant to the standard agents. Despite limitations in the current database, olanzapine is a promising treatment option for patients with schizophrenia.
Collapse
Affiliation(s)
- J C Kando
- Clinical Pharmacy Services, Massachusetts Project, MedManagement, Tewksbury, USA
| | | | | | | | | | | |
Collapse
|
18
|
Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 1997; 25:1-10. [PMID: 9176922 DOI: 10.1016/s0920-9964(96)00098-9] [Citation(s) in RCA: 133] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
UNLABELLED This study assessed the relationships between positive and negative clinical symptoms and specific neuropsychological deficits in a group of stable schizophrenic patients. METHOD Thirty patients were assessed using the Positive and Negative Syndrome Scale (PANSS) for schizophrenia and a battery of cognitive tests. The PANSS assessments were done by a group of raters blind to the results of cognitive tests, while the cognitive tests were conducted by a different group of raters who remained blind to the PANSS scores. RESULTS We found that, although positive and negative symptoms showed a trend toward direct correlation with each other, they correlated with distinct cognitive deficits. Patients with higher negative scores had more perseverative responses, perservative errors, and completed fewer categories on the Wisconsin Card Sorting Test; they also experienced more difficulties on trail making and verbal fluency tests. On the other hand, positive symptoms were associated with poor performance on the Digit Span, particularly the Digit Span Forward. CONCLUSIONS Our findings are in agreement with previous reports that negative symptoms may be associated with poor performance on cognitive tests reflecting particularly frontal function. Positive symptoms, on the other hand, seem to be associated with poor attention, specifically of auditory type, and thus, possibly with dysfunction within the more widespread neural networks underlying attention. Our findings support the hypothesis that positive and negative symptoms may be associated with distinct neuropsychological deficits and thus with distinct neurological substrates and point to the need to address both positive and negative dimensions when studying schizophrenia.
Collapse
Affiliation(s)
- I Berman
- Taunton State Hospital, Harvard Medical School, MA 02780-0997, USA
| | | | | | | | | | | |
Collapse
|
19
|
|
20
|
Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J, True WR, Tsuang MT. How do genes influence marijuana use? The role of subjective effects. Addiction 1997; 92:409-17. [PMID: 9177062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This study investigated determinants of the subjective effects of marijuana and the relationship of subjective effects to marijuana use. Subjects were 8169 twins drawn from the Vietnam Era Twin Registry. Subjects who used marijuana more than five times (n = 2513) reported whether they experienced each of 23 subjective reactions. Factor analysis identified a positive (pleasant) reaction factor and a negative (unpleasant) reaction factor. Both factors were related to duration and frequency of use. Pairs in which both members used marijuana more than five times (MZ = 352 pairs; DZ = 255 pairs) were examined to assess determinants of subjective effects. Approximately one-quarter of the variance in each factor was determined by additive genetic influences; the remaining variance was determined by environmental factors that are not shared by members of a twin pair. The shared or family environment had no detectable influence on either subjective reaction factor.
Collapse
Affiliation(s)
- M J Lyons
- Department of Psychology, Boston University, MA 02215, USA
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Recent studies show that obsessive-compulsive symptoms may occur in many patients with schizophrenia and may predict a poor prognosis. Pilot studies have shown that some schizophrenic patients may improve if a serotonin reuptake blocker is added to their neuroleptic. We have performed a pilot, double-blind, crossover study of clomipramine (CMI) or placebo, added to maintenance psychotropic medication. Six schizophrenic patients with obsessive-compulsive symptoms were studied in a double-blind CMI versus placebo crossover protocol. The patients met DSM-III-R criteria for chronic schizophrenia, experienced obsessive-compulsive symptoms, and had been previously stabilized on their psychiatric medication. The patients were rated at baseline and longitudinally through the study with the Positive and Negative Symptom Scale for Schizophrenia (PANSS) and the Yale Brown Obsessive-Compulsive Scale (YBOCS). An analysis of covariance was used to compare the drug versus placebo effect at the final visit with the baseline rating as a covariate. Ratings on both the YBOCS and the PANSS showed that patients improved significantly more on CMI than on placebo. No patients experienced an exacerbation of psychotic symptoms. Preliminary findings from this double-blind, crossover, pilot study of CMI and placebo, designed to assess the effect of CMI in the treatment of schizophrenic patients with obsessive symptoms, suggest that CMI is superior to placebo in the treatment of obsessions and compulsions and improves overall schizophrenic symptoms. Further studies with larger samples and longer follow-up period are necessary to confirm these preliminary findings.
Collapse
Affiliation(s)
- I Berman
- Commonwealth Research Center, Massachusetts Mental Health Center, Harvard Medical School, Department of Psychiatry, Boston, USA
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
Recent studies suggest that clozapine is more effective than typical neuroleptics for patients with treatment-resistant schizophrenia. Although other investigations suggest that clozapine may also be at least as effective, and probably more so, than typical neuroleptics for individuals with acute psychosis, the toxicity of this drug has caused its use to be restricted to patients who have demonstrated resistance to previous treatment. The hypothesis behind this article, however, is that clozapine may not only be more effective than typical neuroleptics for individuals with "first-episode" schizophrenia but may also lead to a better long-term course in such patients. This hypothesis is based on the clinical literature concerning clinical and biological response to typical and atypical neuroleptic drugs, as well as on preliminary findings from studies of clinical, neuroendocrine, and biochemical effects that occur during treatment with haloperidol but not with clozapine. When examined in light of Wyatt's recent proposal that each period of symptom exacerbation may lay the groundwork for further symptoms and for increasing syndrome severity, the data suggest that clozapine, despite its disturbing side-effect profile, should be studied in controlled double-blind clinical trials during patients' first episode of schizophrenia. If such investigations show that clozapine is more effective than typical neuroleptics for patients with first-episode schizophrenia and results in a better long-term course, then its benefits and risk as a routine first-line treatment for schizophrenia can be considered. The findings of these studies may also lead us to the regular clinical use of new agents that are less toxic than clozapine but have similar clinical and biological profiles.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Massachusetts Mental Health Center, Boston 02115, USA
| | | |
Collapse
|
23
|
Abstract
The goals of the study were to determine the prevalence of obsessive or compulsive (OC) symptoms among chronic schizophrenic patients, and to elucidate the level of function and course of illness in chronic schizophrenic patients with and without such symptoms. Therapists of 102 patients with DSM-III-R diagnoses of chronic schizophrenia reported on their patients' OC symptoms, level of function, and course of illness. Twenty-five percent of the chronic schizophrenic patients presented with significant OC symptoms. The OC schizophrenics had significantly earlier onsets of their illnesses, had spent more time in the hospital in the previous 5 years, and were judged by their therapists to have a lower level of capacity for age-appropriate function. In addition, such patients had been less often employed and less often married, and were more dependent on others. The poorer prognosis for schizophrenic patients with OC symptoms than for those without these symptoms suggests the need for new therapeutic strategies for such patients.
Collapse
Affiliation(s)
- I Berman
- Maimonides Medical Center, Brooklyn, NY
| | | | | | | | | |
Collapse
|
24
|
Green AI, Zalma A, Berman I, DuRand CJ, Salzman C. Clozapine following ECT: a two-step treatment. J Clin Psychiatry 1994; 55:388-90. [PMID: 7929018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Some candidates for clozapine treatment may be unable to be given the drug. They may be so severely ill that they cannot or will not ingest a pill; their psychosis may have so compromised their physical status that use of clozapine, which produces a broad range of side effects, would be unsafe; and/or they may require a very rapid control of their behavior. METHOD Two case reports are described of patients who, although candidates for clozapine, were unable to take or be given the drug. Initial treatment with electroconvulsive therapy (ECT) was tried in both patients prior to use of clozapine. RESULTS In the two cases described, treatment with ECT prior to clozapine stabilized the patients enough that clozapine could be administered. In both cases, the clozapine appeared to perpetuate the initial clinical response produced by the ECT. CONCLUSION These case reports suggest that a two-step strategy of ECT followed by clozapine treatment may both facilitate the use of clozapine in some patients and perpetuate the clinical stability produced by ECT alone.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Harvard Medical School, Boston, MA
| | | | | | | | | |
Collapse
|
25
|
|
26
|
Affiliation(s)
- M Kahn
- Department of Psychiatry, New England Deaconess Hospital, Boston, MA 02215, USA
| | | |
Collapse
|
27
|
Abstract
Eleven acutely psychotic patients with schizophrenia or schizoaffective disorder underwent a 5-7 day drug-washout period (with lorazepam allowed) prior to participating in a 6-week controlled dose haloperidol trial. Patients were evaluated longitudinally with clinical ratings and with plasma measures of the catecholamines dopamine (pDA) and norepinephrine (pNE) and their metabolites, homovanillic acid (pHVA) and 3-methoxy-4-hydroxyphenylglycol (pMHPG). All patients exhibited clinical improvement with haloperidol; the decrease in their Brief Psychiatric Rating Scale (BPRS) scores ranged from 32 to 89%. Measures of pHVA increased within the first week of treatment and returned to baseline by week 5. The pattern of change of pDA resembled that of pHVA. The pattern of change of pNE and pMHPG revealed a decrease over the course of treatment. The early increase and the subsequent decrease in pHVA were strongly correlated with improvement in positive symptoms on the BPRS. These data are consistent with previous reports on the change in pHVA and pMHPG during clinical response to haloperidol. The data on change of pDA and pNE further describe the nature of the biochemical response to this drug.
Collapse
Affiliation(s)
- A I Green
- Massachusetts Mental Health Center, Neuropsychopharmacology/Psychiatric Chemistry Laboratory, Boston
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Reports of characteristic psychiatric symptoms occurring in patients with pancreatic cancer appear regularly in the literature. A review of this literature reveals that symptoms of depression and/or anxiety may appear in approximately 50% of patients with pancreatic cancer before the diagnosis is made. This review proposes that the psychopathology of pancreatic tumors may be linked to tumor-induced changes in neuroendocrine or acid-base systems. Although confirmatory data are lacking, informed speculation centers on the potential role of adrenocorticotropic hormone, parathyroid hormone, thyrotropin-releasing hormone, glucagon, serotonin, insulin, and bicarbonate in the production of depression and/or anxiety in this disease. Elucidation of the pathophysiology of the psychiatric symptoms in patients with pancreatic cancer may provide a marker for early diagnosis of pancreatic neoplasia as well as a probe into the biologic bases of depression and anxiety.
Collapse
Affiliation(s)
- A I Green
- Department of Psychiatry, Massachusetts Mental Health Center, Harvard Medical School, Boston 02115
| | | |
Collapse
|
29
|
Seidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, Tsuang MT. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993; 33:575-84. [PMID: 8101100 DOI: 10.1016/0006-3223(93)90095-u] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The effect of 80%-90% neuroleptic dose reductions on neuropsychological function in schizophrenic and schizoaffective patients was examined in a prospective study. A neuropsychological battery was administered in the week prior to neuroleptic reduction followed by retesting at least 6 weeks postreduction. Patients were retested only if they did not relapse after reduction. The design allowed neuropsychological changes due to neuroleptic medications to be assessed independently of general clinical change. Neuropsychological performance was generally stable and unchanging. However, there was a trend toward significant improvement on a dichotic digits task based in improvement in left ear accuracy. Negative symptoms diminished after reduction. Compared with a normal control group, schizophrenics' initial laterality index showed a significantly exaggerated right ear advantage (REA); after reduction, the REA was no longer different from controls. The findings indicate that neuropsychological changes in a small sample of older nonrelapsing chronic schizophrenics are modest. The data suggest that neuroleptics may impair right hemisphere functions in some patients.
Collapse
Affiliation(s)
- L J Seidman
- Department of Psychiatry, Harvard Medical School, Boston, MA
| | | | | | | | | | | | | |
Collapse
|
30
|
Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 1993; 46:139-49. [PMID: 8483973 DOI: 10.1016/0165-1781(93)90016-a] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The atypical neuroleptic clozapine has an unusual profile of clinical effects and a distinctive spectrum of pharmacological actions. Plasma measures of catecholamines and their metabolites have been used in the past to study the action of typical neuroleptics. We obtained longitudinal assessments of plasma measures of dopamine (pDA), norepinephrine (pNE), and their metabolites, homovanillic acid (pHVA) and 3-methoxy-4-hydroxyphenylglycol (pMHPG), in eight treatment-resistant or treatment-intolerant schizophrenic patients who were treated with clozapine for 12 weeks following a prolonged drug-washout period. Our findings from the study of these eight patients suggest the following: Plasma levels of HVA and possibly NE derived from the neuroleptic-free baseline period may predict response to clozapine; plasma levels of HVA and MHPG decrease during the initial weeks of treatment in responders but not in nonresponders; and plasma levels of DA and NE increase in both responders and nonresponders to clozapine.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Massachusetts Mental Health Center
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Holinger DP, Faux SF, Shenton ME, Sokol NS, Seidman LJ, Green AI, McCarley RW. Reversed temporal region asymmetries of P300 topography in left- and right-handed schizophrenic subjects. Electroencephalogr Clin Neurophysiol 1992; 84:532-7. [PMID: 1280199 DOI: 10.1016/0168-5597(92)90042-a] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The auditory P300 evoked potential was recorded in 36 subjects: left- (LH) and right-handed (RH) schizophrenic males and LH and RH normal controls. LH and RH normals showed no asymmetry in P300 scalp topography. LH and RH schizophrenics, however, showed lateralized asymmetries in temporal scalp regions: left < right P300 voltage asymmetry in RH schizophrenics and left > right P300 voltage asymmetry in LH schizophrenics. These data suggest that the schizophrenic pathology of P300 neural generators is lateralized according to handedness and provide the first evidence that LH and RH schizophrenics can be dissociated based on left-right voltage asymmetries in P300 topography. These findings further emphasize the need for control of handedness in P300 studies of schizophrenia.
Collapse
Affiliation(s)
- D P Holinger
- Department of Psychiatry, Harvard Medical School, Brockton VAMC, MA 02401
| | | | | | | | | | | | | |
Collapse
|
32
|
Berman I, Zalma A, DuRand CJ, Green AI. Clozapine-induced myoclonic jerks and drop attacks. J Clin Psychiatry 1992; 53:329-30. [PMID: 1517198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
33
|
|
34
|
Abstract
Neuroleptic-induced alterations in serum prolactin levels may have important clinical implications. Twenty-two stable schizophrenic patients, taken off medication over a 3-week period, were followed for 40 weeks or until the neuroleptic was reinstituted. Serum prolactin levels were measured during neuroleptic treatment and during the neuroleptic-free period. When serum prolactin levels were plotted over time, 55% of the subjects showed shifting prolactin levels in the shape of a "V" (i.e., a fall in prolactin level preceding an increase in the level) in the early weeks following withdrawal. Subjects with the "V" shape had significantly lower prolactin levels during neuroleptic treatment than those without the "V" shape. The pathophysiological significance of the prolactin "V" pattern is uncertain. It is consistent, however, with transient dopaminergic hyperactivity following neuroleptic withdrawal.
Collapse
Affiliation(s)
- A I Green
- Commonwealth Research Center, Massachusetts Mental Health Center, Boston
| | | | | |
Collapse
|
35
|
Green AI, Salzman C. Clozapine: benefits and risks. Hosp Community Psychiatry 1990; 41:379-80. [PMID: 2158938 DOI: 10.1176/ps.41.4.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- A I Green
- Commonwealth Research Center, Boston, Massachusetts
| | | |
Collapse
|
36
|
Affiliation(s)
- S V Faraone
- Psychiatry Service, VA Medical Center, Brockton, Massachusetts 02401
| | | | | | | | | |
Collapse
|
37
|
Green AI, Bennett MB, Salzman C. An extramural training program in psychopharmacology: one model for a state system. Hosp Community Psychiatry 1989; 40:126-7. [PMID: 2914665 DOI: 10.1176/ps.40.2.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- A I Green
- Psychopharmacology Extramural Training Program, Massachusetts Mental Health Center, Boston
| | | | | |
Collapse
|
38
|
Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 1988; 17:213-23. [PMID: 2897910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Serum prolactin is reliably elevated by the antipsychotic drugs. Prolactin levels have been followed in psychotic patients during the use of these drugs as an indicator of underlying pathophysiology or as a reflection of drug activity. Considerable research is underway to elucidate further the potential clinical and research utility of the prolactin response to neuroleptic drugs.
Collapse
Affiliation(s)
- A I Green
- Harvard Medical School, Boston, Massachusetts
| | | |
Collapse
|
39
|
Green AI, Brown WA. Prolactin and neuroleptic drugs. Neurol Clin 1988; 6:213-23. [PMID: 2898095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Serum prolactin is reliably elevated by the antipsychotic drugs. Prolactin levels have been followed in psychotic patients during the use of these drugs as an indicator of underlying pathophysiology or as a reflection of drug activity. Considerable research is underway to elucidate further the potential clinical and research utility of the prolactin response to neuroleptic drugs.
Collapse
Affiliation(s)
- A I Green
- Harvard Medical School, Boston, Massachusetts
| | | |
Collapse
|
40
|
Salzman C, Green AI, Rodriguez-Villa F, Jaskiw GI. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics 1986; 27:17-22. [PMID: 3952250 DOI: 10.1016/s0033-3182(86)72734-5] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
41
|
Green AI. Thyroid function and affective disorders. Hosp Community Psychiatry 1984; 35:1188-9. [PMID: 6439621 DOI: 10.1176/ps.35.12.1188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
42
|
Kuhar MJ, Green AI, Snyder SH, Gfeller E. Separation of synaptosomes storing catecholamines and gamma-aminobutyric acid in rat corpus striatum. Brain Res 1970; 21:405-17. [PMID: 5456733 DOI: 10.1016/0006-8993(70)90420-8] [Citation(s) in RCA: 56] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
43
|
Green AI, Snyder SH, Iversen LL. Separation of catecholamine-storing synaptosomes in different regions of rat brain. J Pharmacol Exp Ther 1969; 168:264-71. [PMID: 5803310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
|
44
|
Snyder SH, Green AI, Hendley ED. Kinetics of H3-norepinephrine accumulation into slices from different regions of the rat brain. J Pharmacol Exp Ther 1968; 164:90-102. [PMID: 5722109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
|
45
|
|